By ANDREW POLLACK
FEB. 3, 2015
Gilead Sciences sold $ 10.3 billion of its new hepatitis C drug Sovaldi in 2014, a map that brought it close to life the best-promotion drug in the world in only its first year on the market.
The sales map, announced on Tuesday in Gilead’s earnings report for the fourth quarter, falls small of the $ 12.5 billion in sales recorded in 2014 by AbbVie’s autoimmune disease drug Humira, which is believed to be the world’s top-promotion pharmaceutical.
But sales of Sovaldi were lower than they might have been because of Gilead’s introduction of an even newer hepatitis C drug, Harvoni, which recorded $ 2.1 billion in sales in view of the fact that its approval in October. Together Sovaldi and Harvoni achieved $ 12.4 billion in sales, just small of Humira’s total.
No comments:
Post a Comment